Tests tirofiban with tenecteplase in people with acute ischemic stroke
Tests tirofiban alongside tenecteplase in adults having an acute ischemic stroke.
Plain-language title generated from the registry record
Registry title: Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke
Key facts
- Where
- Chifeng, Chuzhou, Dalian, Ganzhou, Huaihua, Huanggang, Ji’an, Jiujiang, Longyan, Nanchang, Nanning, Shaoyang, Songyuan, Xiangtan, Yichang, Yichun, Yingtan, and Yueyang, ChinaSee the 38 sites
- Phase
- Phase 3
Where in China
- Zhongmeng Hospital of Hexigten BannerChifeng, ChinaTaking people
- Mingguang People's HospitalChuzhou, ChinaTaking people
- Dalian Municipal Central HospitalDalian, ChinaTaking people
- Ganzhou Municipal HospitalGanzhou, ChinaTaking people
- Ganzhou People's HospitalGanzhou, ChinaTaking people
- Nankang TCM HospitalGanzhou, ChinaTaking people
- People's Hospital of Anyuan CountyGanzhou, ChinaTaking people
- People's Hospital of Chongyi CountyGanzhou, ChinaTaking people
- People's Hospital of Dayu CountyGanzhou, ChinaTaking people
- People's Hospital of Ganxian DistrictGanzhou, ChinaTaking people
- People's Hospital of Quannan CountyGanzhou, ChinaTaking people
- People's Hospital of RuiJin CityGanzhou, ChinaTaking people
- People's Hospital of Shangyou CountyGanzhou, ChinaTaking people
- People's Hospital of Shicheng CountyGanzhou, ChinaTaking people
- People's Hospital of Xinfeng CountyGanzhou, ChinaTaking people
- People's Hospital of Xunwu CountyGanzhou, ChinaTaking people
- People's Hospital of Yudu CountyGanzhou, ChinaTaking people
- Second Hospital of Xingguo CountyGanzhou, ChinaTaking people
- Second People's Hospital of Yudu CountyGanzhou, ChinaTaking people
- The People's Hospital of Ningdu CountyGanzhou, ChinaTaking people
- Traditional Chinese Medicine Hospital of Xingguo CountyGanzhou, ChinaTaking people
- Traditional Chinese Medicine Hospital of Yudu CountyGanzhou, ChinaTaking people
- Hunan Xupu Chengnan HospitalHuaihua, ChinaTaking people
- Huangmei People's HospitalHuanggang, ChinaTaking people
- Ji'an Central People's HospitalJi’an, ChinaTaking people
- People's Hospital of Wan'an countyJi’an, ChinaTaking people
- Affiliated Hospital of Jiujiang UniversityJiujiang, ChinaTaking people
- Longyan People´s Hospital, Longyan CityLongyan, ChinaTaking people
- Jiangxi Provincial People's HospitalNanchang, ChinaTaking people
- The Second Affiliated Hospital of Guangxi Medical UniversityNanning, ChinaTaking people
- People's Hospital Of ShaodongShaoyang, ChinaTaking people
- Songyuan Jilin Oilfield HospitalSongyuan, ChinaTaking people
- Shaoshan People's HospitalXiangtan, ChinaTaking people
- Xiangtan Central HospitallXiangtan, ChinaTaking people
- Yiling People's Hospital of Yichang cityYichang, ChinaTaking people
- People's Hospital of YichunYichun, ChinaTaking people
- Yingtan People's HospitalYingtan, ChinaTaking people
- Hunan University of Medicine Affiliated Pingjiang HospitalYueyang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Second Affiliated Hospital of Guangxi Medical University
- Trial code
- NCT05604638
- Record updated
- 24 December 2025
- Original description
The purpose of this study is to assess the safety and efficacy of early administration of tirofiban in patients treated with tenecteplase for acute ischemic stroke.Read full original descriptionShow less
Safety and Efficacy of Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke
The purpose of this study is to assess the safety and efficacy of early administration of tirofiban in patients treated with tenecteplase for acute ischemic stroke.
Inclusion: Age ≥ 18 years old; Within 4-24 hours after intravenous thrombolytic therapy with tenerplase for acute ischemic stroke, there was no significant change in symptoms compared to the baseline (defined as an increase or decrease of 0 or 1 point in the NIHSS score), and neurological function deteriorated (defined as an increase of ≥ 2 in the NIHSS score compared to the baseline) Fluctuations in neurological function (defined as an increase of 4 points or more in the NIHSS score compared to the baseline and then a decrease of 4 points or more); NIHSS ≥ 4 points before randomization; The patient or their family members sign a written informed consent form.
Exclusion: Prior neurological or psychiatric illness that prevents assessment of neurological function; Intracranial hemorrhage was confirmed by CT or MRI after intravenous thrombolysis and before randomization; Renal insufficiency, glomerular filtration rate < 30 mL/min; Allergic to tirofiban, nickel, titanium or their alloys; Pre-existing bleeding disease, severe heart, liver, or kidney disease, or sepsis; Life expectancy of any advanced disease < 6 months; Confirmed or suspected cardioembolic stroke mechanisms, including any of the following: documented cardiac sources of thromboembolism: chronic or paroxysmal atrial fibrillation, rheumatic mitral stenosis, prosthetic heart valves, infective endocarditis, intracardiac thrombus or implanted prosthetic material, dilated cardiomyopathy (left ventricular ejection fraction <40%), or spontaneous echo contrast in the left atrium; other laboratory-confirmed embolic sources: patent foramen ovale with concomitant atrial septal aneurysm, or cryptogenic stroke with a CHADS-VASC score ≥ 2 indicating high thromboembolic risk; Blood platelet count was lower than 100×10\^9/L; CTA/MRA/DSA showed occlusion of the internal carotid artery, middle cerebral artery M1, M2 or M3 segment, anterior cerebral artery A1, A2 or A3 segment, posterior cerebral artery P1, P2 or P3, vertebral or basilar artery; Pregnant or lactating women; Brain tumors with a space-occupying effect on imaging (other than micromeningiomas); Intracranial aneurysm, arteriovenous malformation; Participating in other clinical trials.